Pamidronate disodium pentahydrate is used primarily in the treatment of bone disorders such as Paget's disease and complications associated with cancer, including hypercalcemia of malignancy and osteolytic lesions from breast cancer or multiple myeloma. It works by inhibiting bone resorption through suppression of osteoclast activity, which helps maintain bone density and reduce the risk of fractures. In oncology, it effectively manages hypercalcemia caused by cancer-related bone breakdown. Additionally, it alleviates bone pain in patients with metastatic bone disease, improving quality of life. Administered intravenously, it requires careful monitoring for proper dosage and to minimize side effects.